{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:18:11Z","timestamp":1768407491871,"version":"3.49.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pediatr Rep"],"DOI":"10.1007\/s40124-025-00349-7","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T23:30:40Z","timestamp":1751067040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pediatric Hypertriglyceridemia: Lipoprotein Metabolism, Etiology, and Management"],"prefix":"10.1007","volume":"13","author":[{"given":"Hidenori","family":"Moriyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Nina","family":"Ham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"issue":"1","key":"349_CR1","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1542\/peds.2006-1801","volume":"120","author":"EM Haney","year":"2007","unstructured":"Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipid disorders in children and adolescents: Systematic evidence review for the US preventive services task force. Pediatrics. 2007;120(1):e189\u2013214.","journal-title":"Pediatrics"},{"issue":"3","key":"349_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ecl.2022.02.008","volume":"51","author":"KR Feingold","year":"2022","unstructured":"Feingold KR. Lipid and lipoprotein metabolism. Endocrinol Metab Clin North Am. 2022;51(3):437\u201358.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"349_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1515\/mr-2021-0004","volume":"1","author":"G Liu","year":"2021","unstructured":"Liu G, Lai P, Guo J, Wang Y, Xian X. Genetically-engineered hamster models: applications and perspective in dyslipidemia and atherosclerosis-related cardiovascular disease. Med Rev. 2021;1(1):92\u2013110.","journal-title":"Med Rev"},{"key":"349_CR4","doi-asserted-by":"crossref","unstructured":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128 Suppl 5(Suppl 5):S213\u201356.","DOI":"10.1542\/peds.2009-2107C"},{"issue":"19","key":"349_CR5","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1001\/jama.2019.4984","volume":"321","author":"AM Perak","year":"2019","unstructured":"Perak AM, Ning H, Kit BK, de Ferranti SD, Van Horn LV, Wilkins JT, et al. Trends in levels of lipids and apolipoprotein B in US youths aged 6 to 19 years, 1999\u20132016. JAMA. 2019;321(19):1895\u2013905.","journal-title":"JAMA"},{"issue":"3","key":"349_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.7570\/jomes.2018.27.3.143","volume":"27","author":"MK Jung","year":"2018","unstructured":"Jung MK, Yoo EG. Hypertriglyceridemia in obese children and adolescents. J Obes Metab Syndr. 2018;27(3):143\u20139.","journal-title":"J Obes Metab Syndr"},{"issue":"7","key":"349_CR7","doi-asserted-by":"publisher","first-page":"e2421724","DOI":"10.1001\/jamanetworkopen.2024.21724","volume":"7","author":"AM Thompson-Paul","year":"2024","unstructured":"Thompson-Paul AM, Kraus EM, Porter RM, Pierce SL, Kompaniyets L, Sekkarie A, et al. Pediatric lipid screening prevalence using nationwide electronic medical records. JAMA Netw Open. 2024;7(7):e2421724.","journal-title":"JAMA Netw Open"},{"issue":"5 Suppl","key":"349_CR8","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jacl.2015.04.004","volume":"9","author":"AS Shah","year":"2015","unstructured":"Shah AS, Wilson DP. Primary hypertriglyceridemia in children and adolescents. J Clin Lipidol. 2015;9(5 Suppl):S20\u20138.","journal-title":"J Clin Lipidol"},{"issue":"5 Suppl","key":"349_CR9","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.jacl.2015.04.006","volume":"9","author":"PR Blackett","year":"2015","unstructured":"Blackett PR, Wilson DP, McNeal CJ. Secondary hypertriglyceridemia in children and adolescents. J Clin Lipidol. 2015;9(5 Suppl):S29\u201340.","journal-title":"J Clin Lipidol"},{"key":"349_CR10","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jpeds.2021.12.017","volume":"243","author":"DP Wilson","year":"2022","unstructured":"Wilson DP, Williams L, Kavey RW. Hypertriglyceridemia in Youth. J Pediatr. 2022;243:200\u20137.","journal-title":"J Pediatr"},{"issue":"11","key":"349_CR11","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.3324\/haematol.2014.109413","volume":"99","author":"WH Tong","year":"2014","unstructured":"Tong WH, Pieters R, de Groot-Kruseman HA, Hop WC, Boos J, Tissing WJ, et al. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia. Haematologica. 2014;99(11):1716\u201321.","journal-title":"Haematologica"},{"key":"349_CR12","unstructured":"Herink M, Ito MK. Medication induced changes in lipid and lipoproteins. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright \u00a9 2000\u20132025, MDText.com, Inc.; 2000."},{"key":"349_CR13","unstructured":"Shah AS, Wilson DP. Genetic disorders causing hypertriglyceridemia in children and adolescents. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright \u00a9 2000\u20132025, MDText.com, Inc.; 2000."},{"issue":"11","key":"349_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11883-020-00885-1","volume":"22","author":"A Gallo","year":"2020","unstructured":"Gallo A, B\u00e9liard S, D\u2019Erasmo L, Bruckert E. Familial chylomicronemia syndrome (FCS): Recent data on diagnosis and treatment. Curr Atheroscler Rep. 2020;22(11):63.","journal-title":"Curr Atheroscler Rep"},{"key":"349_CR15","doi-asserted-by":"publisher","first-page":"m3109","DOI":"10.1136\/bmj.m3109","volume":"371","author":"V Simha","year":"2020","unstructured":"Simha V. Management of hypertriglyceridemia. Bmj. 2020;371:m3109.","journal-title":"Bmj"},{"issue":"5","key":"349_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1089\/jir.1997.17.241","volume":"17","author":"D Sgarabotto","year":"1997","unstructured":"Sgarabotto D, Vianello F, Stefani PM, Scano F, Sartori R, Caenazzo A, et al. Hypertriglyceridemia during long-term interferon-\u03b1 therapy in a series of hematologic patients. J Interferon Cytokine Res. 1997;17(5):241\u20134.","journal-title":"J Interferon Cytokine Res"},{"issue":"20","key":"349_CR17","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","volume":"123","author":"M Miller","year":"2011","unstructured":"Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease. Circulation. 2011;123(20):2292\u2013333.","journal-title":"Circulation"},{"issue":"4","key":"349_CR18","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1172\/JCI115114","volume":"87","author":"D Ameis","year":"1991","unstructured":"Ameis D, Kobayashi J, Davis RC, Ben-Zeev O, Malloy MJ, Kane JP, et al. Familial chylomicronemia (type I hyperlipoproteinemia) due to a single missense mutation in the lipoprotein lipase gene. J Clin Invest. 1991;87(4):1165\u201370.","journal-title":"J Clin Invest"},{"issue":"4","key":"349_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jacl.2018.03.093","volume":"12","author":"RA Hegele","year":"2018","unstructured":"Hegele RA, Berberich AJ, Ban MR, Wang J, Digenio A, Alexander VJ, et al. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. J Clin Lipidol. 2018;12(4):920-7.e4.","journal-title":"J Clin Lipidol"},{"issue":"17","key":"349_CR20","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1056\/NEJMoa1611930","volume":"376","author":"AP Beigneux","year":"2017","unstructured":"Beigneux AP, Miyashita K, Ploug M, Blom DJ, Ai M, Linton MF, et al. Autoantibodies against GPIHBP1 as a cause of hypertriglyceridemia. N Engl J Med. 2017;376(17):1647\u201358.","journal-title":"N Engl J Med"},{"issue":"5","key":"349_CR21","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1210\/jc.2013-3619","volume":"99","author":"H Yamamoto","year":"2014","unstructured":"Yamamoto H, Tanaka M, Yoshiga S, Funahashi T, Shimomura I, Kihara S. Autoimmune severe hypertriglyceridemia induced by anti-apolipoprotein C-II antibody. J Clin Endocrinol Metab. 2014;99(5):1525\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"349_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/cge.14185","volume":"102","author":"BE Heidemann","year":"2022","unstructured":"Heidemann BE, Koopal C, Baass A, Defesche JC, Zuurbier L, Mulder MT, et al. Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene. Clin Genet. 2022;102(4):253\u201361.","journal-title":"Clin Genet"},{"key":"349_CR23","doi-asserted-by":"publisher","first-page":"102954","DOI":"10.1016\/j.ebiom.2020.102954","volume":"59","author":"AL Lumsden","year":"2020","unstructured":"Lumsden AL, Mulugeta A, Zhou A, Hypp\u00f6nen E. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank. EBioMedicine. 2020;59:102954.","journal-title":"EBioMedicine"},{"key":"349_CR24","doi-asserted-by":"publisher","first-page":"155919","DOI":"10.1016\/j.metabol.2024.155919","volume":"156","author":"A Zeljkovic","year":"2024","unstructured":"Zeljkovic A, Vekic J, Stefanovic A. Obesity and dyslipidemia in early life: Impact on cardiometabolic risk. Metabolism. 2024;156:155919.","journal-title":"Metabolism"},{"issue":"1","key":"349_CR25","first-page":"635740","volume":"2014","author":"A Hinson","year":"2014","unstructured":"Hinson A, Newbern D, Linardic CM. Asparaginase-induced hypertriglyceridemia presenting as pseudohyponatremia during leukemia treatment. Case Rep Pediatr. 2014;2014(1):635740.","journal-title":"Case Rep Pediatr"},{"issue":"7","key":"349_CR26","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","volume":"8","author":"BL Kasiske","year":"2008","unstructured":"Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant. 2008;8(7):1384\u201392.","journal-title":"Am J Transplant"},{"issue":"9637","key":"349_CR27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (London, England). 2008;372(9637):449\u201356.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"349_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12944-020-01424-2","volume":"19","author":"E Garcia","year":"2020","unstructured":"Garcia E, Bennett DW, Connelly MA, Jeyarajah EJ, Warf FC, Shalaurova I, et al. The extended lipid panel assay: a clinically-deployed high-throughput nuclear magnetic resonance method for the simultaneous measurement of lipids and Apolipoprotein B. Lipids Health Dis. 2020;19(1):247.","journal-title":"Lipids Health Dis"},{"key":"349_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.bbacli.2015.01.005","volume":"3","author":"A Hafiane","year":"2015","unstructured":"Hafiane A, Genest J. High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk. BBA Clin. 2015;3:175\u201388.","journal-title":"BBA Clin"},{"issue":"11","key":"349_CR30","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation. 2019;140(11):e596\u2013646.","journal-title":"Circulation"},{"issue":"1","key":"349_CR31","doi-asserted-by":"publisher","first-page":"100148","DOI":"10.1016\/j.jlr.2021.100148","volume":"63","author":"HN Ginsberg","year":"2022","unstructured":"Ginsberg HN, Rosenson RS, Hovingh GK, Letierce A, Samuel R, Poulouin Y, et al. LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials. J Lipid Res. 2022;63(1):100148.","journal-title":"J Lipid Res"},{"key":"349_CR32","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1017\/jns.2021.73","volume":"10","author":"BH Keirns","year":"2021","unstructured":"Keirns BH, Sciarrillo CM, Koemel NA, Emerson SR. Fasting, non-fasting and postprandial triglycerides for screening cardiometabolic risk. J Nutr Sci. 2021;10:e75.","journal-title":"J Nutr Sci"},{"issue":"9","key":"349_CR33","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1542\/pir.2016-0138","volume":"38","author":"B Valaiyapathi","year":"2017","unstructured":"Valaiyapathi B, Sunil B, Ashraf AP. Approach to hypertriglyceridemia in the pediatric population. Pediatr Rev. 2017;38(9):424\u201334.","journal-title":"Pediatr Rev"},{"issue":"3","key":"349_CR34","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1373\/clinchem.2010.157164","volume":"57","author":"A Langsted","year":"2011","unstructured":"Langsted A, Nordestgaard BG. Nonfasting Lipids, Lipoproteins, and Apolipoproteins in Individuals with and without Diabetes: 58 434 Individuals from the Copenhagen General Population Study. Clin Chem. 2011;57(3):482\u20139.","journal-title":"Clin Chem"},{"issue":"3","key":"349_CR35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1542\/peds.2011-0844","volume":"128","author":"MJ Steiner","year":"2011","unstructured":"Steiner MJ, Skinner AC, Perrin EM. Fasting might not be necessary before lipid screening: A nationally representative cross-sectional study. Pediatrics. 2011;128(3):463\u201370.","journal-title":"Pediatrics"},{"issue":"12","key":"349_CR36","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.3390\/jcm12124076","volume":"12","author":"F Aziz","year":"2023","unstructured":"Aziz F, Sam R, Lew SQ, Massie L, Misra M, Roumelioti M-E, et al. Pseudohyponatremia: Mechanism, diagnosis, clinical associations and management. J Clin Med. 2023;12(12):4076.","journal-title":"J Clin Med"},{"issue":"12","key":"349_CR37","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1161\/ATVBAHA.122.318445","volume":"42","author":"MR Deshotels","year":"2022","unstructured":"Deshotels MR, Hadley TD, Roth M, Agha AM, Pulipati VP, Nugent AK, et al. Genetic testing for hypertriglyceridemia in academic lipid clinics: implications for precision medicine\u2014brief report. Arterioscler Thromb Vasc Biol. 2022;42(12):1461\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"349_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/01.mcg.0000436438.60145.5a","volume":"48","author":"J Scherer","year":"2014","unstructured":"Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014;48(3):195\u2013203.","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"349_CR39","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1210\/clinem\/dgae371","volume":"110","author":"F Tavaglione","year":"2024","unstructured":"Tavaglione F, Marafioti G, Romeo S, Jamialahmadi O. Machine learning reveals the contribution of lipoproteins to liver triglyceride content and inflammation. J Clin Endocrinol Metab. 2024;110(1):218\u201327.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"349_CR40","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.3390\/nu14051104","volume":"14","author":"KP Luna-Castillo","year":"2022","unstructured":"Luna-Castillo KP, Olivares-Ochoa XC, Hern\u00e1ndez-Ruiz RG, Llamas-Covarrubias IM, Rodr\u00edguez-Reyes SC, Betancourt-N\u00fa\u00f1ez A, et al. The effect of dietary interventions on hypertriglyceridemia: From public health to molecular nutrition evidence. Nutrients. 2022;14(5):1104.","journal-title":"Nutrients"},{"issue":"5","key":"349_CR41","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3390\/nu15051088","volume":"15","author":"ME Capra","year":"2023","unstructured":"Capra ME, Biasucci G, Banderali G, Pederiva C. Nutritional treatment of hypertriglyceridemia in childhood: From healthy-heart counselling to life-saving diet. Nutrients. 2023;15(5):1088.","journal-title":"Nutrients"},{"issue":"7","key":"349_CR42","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3945\/jn.117.248641","volume":"147","author":"KC Maki","year":"2017","unstructured":"Maki KC, Palacios OM, Lindner E, Nieman KM, Bell M, Sorce J. Replacement of refined starches and added sugars with egg protein and unsaturated fats increases insulin sensitivity and lowers triglycerides in overweight or obese adults with elevated triglycerides. J Nutr. 2017;147(7):1267\u201374.","journal-title":"J Nutr"},{"issue":"11","key":"349_CR43","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrm4074","volume":"16","author":"Y Wang","year":"2015","unstructured":"Wang Y, Viscarra J, Kim SJ, Sul HS. Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol. 2015;16(11):678\u201389.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"349_CR44","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/ajcn\/85.6.1511","volume":"85","author":"MF Chong","year":"2007","unstructured":"Chong MF, Fielding BA, Frayn KN. Mechanisms for the acute effect of fructose on postprandial lipemia. Am J Clin Nutr. 2007;85(6):1511\u201320.","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"349_CR45","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.109.192627","volume":"120","author":"RK Johnson","year":"2009","unstructured":"Johnson RK, Appel LJ, Brands M, Howard BV, Lefevre M, Lustig RH, et al. Dietary sugars intake and cardiovascular health. Circulation. 2009;120(11):1011\u201320.","journal-title":"Circulation"},{"issue":"11","key":"349_CR46","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s11883-024-01237-z","volume":"26","author":"CA Gagnon","year":"2024","unstructured":"Gagnon CA, Ashraf AP. Beyond the guidelines: Perspectives on management of pediatric patients with hypertriglyceridemia. Curr Atheroscler Rep. 2024;26(11):617\u201328.","journal-title":"Curr Atheroscler Rep"},{"key":"349_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.29219\/fnr.v66.8242","volume":"66","author":"EK Arnesen","year":"2022","unstructured":"Arnesen EK, Thorisdottir B, Lamberg-Allardt C, B\u00e4rebring L, Nwaru B, Dierkes J, et al. Protein intake in children and growth and risk of overweight or obesity: A systematic review and meta-analysis. Food Nutr Res. 2022;66:10\u201329219.","journal-title":"Food Nutr Res"},{"issue":"1","key":"349_CR48","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12944-017-0515-5","volume":"16","author":"Y Wang","year":"2017","unstructured":"Wang Y, Xu D. Effects of aerobic exercise on lipids and lipoproteins. Lipids Health Dis. 2017;16(1):132.","journal-title":"Lipids Health Dis"},{"issue":"5","key":"349_CR49","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jshs.2021.07.006","volume":"11","author":"L Alvarez-Jimenez","year":"2022","unstructured":"Alvarez-Jimenez L, Moreno-Caba\u00f1as A, Ramirez-Jimenez M, Morales-Palomo F, Ortega JF, Mora-Rodriguez R. Effectiveness of statins vs. exercise on reducing postprandial hypertriglyceridemia in dyslipidemic population: A systematic review and network meta-analysis. J Sport Health Sci. 2022;11(5):567\u201377.","journal-title":"J Sport Health Sci"},{"issue":"11","key":"349_CR50","first-page":"Cd009753","volume":"11","author":"T Jakob","year":"2016","unstructured":"Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-Gonz\u00e1lez I, Briel M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev. 2016;11(11):Cd009753.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"349_CR51","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jacl.2008.02.003","volume":"2","author":"CM Smalley","year":"2008","unstructured":"Smalley CM, Goldberg SJ. A pilot study in the efficacy and safety of gemfibrozil in a pediatric population. J Clin Lipidol. 2008;2(2):106\u201311.","journal-title":"J Clin Lipidol"},{"issue":"9500","key":"349_CR52","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (London, England). 2005;366(9500):1849\u201361.","journal-title":"Lancet (London, England)"},{"issue":"17","key":"349_CR53","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563\u201374.","journal-title":"N Engl J Med"},{"issue":"21","key":"349_CR54","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387(21):1923\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"349_CR55","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12944-016-0286-4","volume":"15","author":"J Backes","year":"2016","unstructured":"Backes J, Anzalone D, Hilleman D, Catini J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids Health Dis. 2016;15(1):118.","journal-title":"Lipids Health Dis"},{"issue":"5","key":"349_CR56","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/0009922814528032","volume":"53","author":"SD de Ferranti","year":"2014","unstructured":"de Ferranti SD, Milliren CE, Denhoff ER, Steltz SK, Selamet Tierney ES, Feldman HA, et al. Using high-dose omega-3 fatty acid supplements to lower triglyceride levels in 10- to 19-year-olds. Clin Pediatr (Phila). 2014;53(5):428\u201338.","journal-title":"Clin Pediatr (Phila)"},{"issue":"8","key":"349_CR57","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1515\/jpem-2018-0409","volume":"32","author":"BE Del-R\u00edo-Navarro","year":"2019","unstructured":"Del-R\u00edo-Navarro BE, Miranda-Lora AL, Huang F, Hall-Mondragon MS, Leija-Mart\u00ednez JJ. Effect of supplementation with omega-3 fatty acids on hypertriglyceridemia in pediatric patients with obesity. J Pediatr Endocrinol Metab. 2019;32(8):811\u20139.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"349_CR58","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jnutbio.2018.10.012","volume":"64","author":"F Huang","year":"2019","unstructured":"Huang F, Del-R\u00edo-Navarro BE, Leija-Martinez J, Torres-Alcantara S, Ruiz-Bedolla E, Hern\u00e1ndez-Cadena L, et al. Effect of omega-3 fatty acids supplementation combined with lifestyle intervention on adipokines and biomarkers of endothelial dysfunction in obese adolescents with hypertriglyceridemia. J Nutr Biochem. 2019;64:162\u20139.","journal-title":"J Nutr Biochem"},{"issue":"8","key":"349_CR59","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/eurjpc\/zwae003","volume":"31","author":"G Kaur","year":"2024","unstructured":"Kaur G, Mason RP, Steg PG, Bhatt DL. Omega-3 fatty acids for cardiovascular event lowering. Eur J Prev Cardiol. 2024;31(8):1005\u201314.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"349_CR60","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"6","key":"349_CR61","doi-asserted-by":"publisher","first-page":"e220019","DOI":"10.1530\/EC-22-0019","volume":"11","author":"ML Chan","year":"2022","unstructured":"Chan ML, Shiu SW, Cheung CL, Yu-Hung Leung A, Tan KC. Effects of statins on the inducible degrader of low-density lipoprotein receptor in familial hypercholesterolemia. Endocr Connect. 2022;11(6):e220019.","journal-title":"Endocr Connect."},{"issue":"2","key":"349_CR62","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12020-020-02302-8","volume":"69","author":"P Anagnostis","year":"2020","unstructured":"Anagnostis P, Vaitsi K, Kleitsioti P, Mantsiou C, Pavlogiannis K, Athyros VG, et al. Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. Endocrine. 2020;69(2):249\u201361.","journal-title":"Endocrine"},{"issue":"16","key":"349_CR63","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","volume":"69","author":"NO Stitziel","year":"2017","unstructured":"Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 Deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69(16):2054\u201363.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"349_CR64","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","volume":"149","author":"A Wiegman","year":"2024","unstructured":"Wiegman A, Greber-Platzer S, Ali S, Reijman MD, Brinton EA, Charng MJ, et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. Circulation. 2024;149(5):343\u201353.","journal-title":"Circulation"},{"issue":"8","key":"349_CR65","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320.","journal-title":"N Engl J Med"},{"issue":"3","key":"349_CR66","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","volume":"29","author":"RS Rosenson","year":"2023","unstructured":"Rosenson RS, Gaudet D, Ballantyne CM, Baum SJ, Bergeron J, Kershaw EE, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023;29(3):729\u201337.","journal-title":"Nat Med"},{"key":"349_CR67","doi-asserted-by":"publisher","unstructured":"Rosenson RS, Rader DJ, Ali S, Banerjee P, McGinniss J, Pordy R. Evinacumab reduces triglyceride-rich lipoproteins in patients with hyperlipidemia: A post-hoc analysis of three randomized clinical trials. Cardiovasc Drugs Ther. 2024. https:\/\/doi.org\/10.1007\/s10557-024-07567-z","DOI":"10.1007\/s10557-024-07567-z"},{"issue":"10","key":"349_CR68","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","volume":"391","author":"RS Rosenson","year":"2024","unstructured":"Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia. N Engl J Med. 2024;391(10):913\u201325.","journal-title":"N Engl J Med"},{"issue":"40","key":"349_CR69","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","volume":"41","author":"D Gaudet","year":"2020","unstructured":"Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Bartlett VJ, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 2020;41(40):3936\u201345.","journal-title":"Eur Heart J"},{"issue":"6","key":"349_CR70","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and Triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381(6):531\u201342.","journal-title":"N Engl J Med"},{"issue":"19","key":"349_CR71","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","volume":"390","author":"ESG Stroes","year":"2024","unstructured":"Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390(19):1781\u201392.","journal-title":"N Engl J Med"},{"issue":"2","key":"349_CR72","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa2409368","volume":"392","author":"GF Watts","year":"2025","unstructured":"Watts GF, Rosenson RS, Hegele RA, Goldberg IJ, Gallo A, Mertens A, et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med. 2025;392(2):127\u201337.","journal-title":"N Engl J Med"},{"issue":"7","key":"349_CR73","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: The SHASTA-2 randomized clinical trial. JAMA Cardiol. 2024;9(7):620\u201330.","journal-title":"JAMA Cardiol"},{"issue":"10","key":"349_CR74","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","volume":"391","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med. 2024;391(10):899\u2013912.","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s40124-025-00369-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000}}],"container-title":["Current Pediatrics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40124-025-00349-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40124-025-00349-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40124-025-00349-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:06:39Z","timestamp":1764180399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40124-025-00349-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["349"],"URL":"https:\/\/doi.org\/10.1007\/s40124-025-00349-7","relation":{},"ISSN":["2167-4841"],"issn-type":[{"value":"2167-4841","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,28]]},"assertion":[{"value":"17 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author noticed a few items that still require corrections especially in Table 1.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40124-025-00369-3","URL":"https:\/\/doi.org\/10.1007\/s40124-025-00369-3","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}